The efficacy of BNT162b2 (Pfizer–BioNTech) and CoronaVac vaccines in patients with cancer

Abstract

Although vaccination is efficacious and prevents infection in the general population, there is limited data about Coronavirus disease-19 (Covid-19) occurrence after vaccination in cancer patients. It was aimed to evaluate the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines against Covid-19 in patients with cancer. In this single-center, retrospective, cross-sectional, and descriptive study, the data of cancer patients referred to the medical oncology clinic of a university hospital were analyzed. The sample of the study consisted of cancer patients who had Covid-19 or were vaccinated against Covid-19. A total number of 2578 patients were included in the study. Of the patients, 2000 have never been infected with severe acute respiratory syndrome coronavirus and 578 patients have had a positive reversetranscription polymerase chain reaction (RT-PCR) for Covid-19. It was found that 2094 patients (81.2%) were fully vaccinated, and 484 patients (18.

The Actual Status of Hospitals as COVID-19 Vaccination Clinics in China and Safety Monitoring of Inactivated Vaccine: A Cross-Sectional Study

“…This study showed no difference between BNT162b2 and CoronaVac in an intragroup comparison of patients vaccinated with the total dose. 28 AZD1222 and Sputnik V are both adenovirus vector vaccines, which are 65%-91.6% effective against historical strains. 27 The side effects of the AZD-1222 vaccine were more evident than the Sputnik V vaccine.…”

Letter to the Editor: The efficacy of BNT162b2 (Pfizer–BioNTech) and CoronaVac vaccines in patients with cancer

“…In Table 1, we shared our results for Table 2 by Simsek. 1 Although the test statistics and overall p values of the full-dose vaccination and the vaccines were like the original article, 1 the test statistics value for the vaccine groups was different. Also, we found an insignificant difference between two doses of BNT162b2 and two doses of CoronaVac and one dose of BNT162b2 in contrast to the original article.…”

“…First, the efficacy of the full-dose vaccination cannot be demonstrated because of the design of the study. 1 Incompletedose vaccinated Covid-19 negative patients were not included in this study, 1 which resulted in selection bias. 2 We think the author should have stated this in the limitation section.…”

“…Thus, we reanalyzed the problematic part of the published data with Pearson's χ 2 test and Holm-Bonferroni correction (more flexible than classic Bonferroni) 6,7 to adjust the p values of pair-wise comparisons in R software (version 4.2). 8 For Table 3 by Simsek, 1 we calculated similar test statistics and p value as the author did. In Table 1, we shared our results for Table 2 by Simsek.…”

Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies

“…March 2020 to December 2021 was performed to assess the effectiveness of vaccination with BNT162b2 or CoronaVac against COVID-19[101]. No significant difference in COVID-19 risk between recipients of two doses of BNT162b2 and three doses of CoronaVac vaccine was observed.…”